Developing a vaginal ring to treat and prevent genital herpes
Official title: IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes
Funded at Auritec Pharmaceuticals, INC. · NIH-10929431 · Data updated 2026-11-12
This study is testing a new type of vaginal ring that slowly releases a medication called pritelivir to help treat and prevent genital herpes, aiming to offer a better treatment option for those affected by this common condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auritec Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Pasadena, United States) |
| Project start | February 1, 2018 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,025,000 |
| NIH project number | 5R44AI136201-05 |
| Project ID | NIH-10929431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who are at risk of or currently suffering from genital herpes.
✕Less likely to help
Patients who do not have genital herpes or are not at risk for the infection may not benefit from this research.
What this research studies
This research focuses on creating a sustained-release intravaginal ring that delivers pritelivir, a promising antiviral medication, to treat and prevent genital herpes. Genital herpes is a widespread condition affecting millions, and current treatment options are limited. The study aims to utilize a novel platform technology that has previously been successful in delivering antiviral agents effectively. By testing the safety and effectiveness of this new delivery method in preclinical models, the research seeks to provide a more effective treatment option for patients.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment and prevention method for genital herpes, improving the quality of life for many patients.
How similar studies have gone: Previous research has shown success with similar sustained-release delivery systems for antiviral agents, indicating potential for this approach.
Where this research is happening
-
Auritec Pharmaceuticals, INC.
Pasadena, United States Active
Researchers
- Principal investigator: Smith, Thomas J. — Auritec Pharmaceuticals, INC.
- Study coordinator: Smith, Thomas J.
Related research
Other NIH-funded projects on the same topics.
-
Long-acting brexpiprazole for agitation in Alzheimer’s disease dementia
A long-acting injectable form of brexpiprazole is being developed to help reduce agitation in people with Alzheimer’s disease dementia, with potential uses in schizophrenia and major depressive disorder.
-
Long-lasting pritelivir vaginal ring to treat and prevent genital herpes
A vaginal ring that slowly releases the antiviral pritelivir to help treat and lower the chance of genital herpes outbreaks for people with this infection.
-
A long-lasting injectable treatment for preventing organ transplant rejection
This study is testing a new long-lasting injection of tacrolimus, a medicine that helps prevent organ rejection in transplant patients, so you won’t have to take daily pills and can maintain steady levels of the drug for a whole month after just one shot.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.